1. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Issue 10075 (25th March 2017) Authors: Aletaha, Daniel; Bingham, Clifton O; Tanaka, Yoshiya; Agarwal, Prasheen; Kurrasch, Regina; Tak, Paul P; Popik, Sharon Journal: Lancet Issue: Volume 389:Issue 10075(2017) Page Start: 1206 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Issue 10324 (5th February 2022) Authors: Polizzotto, Mark N.; Nordwall, Jacqueline; Babiker, Abdel G.; Phillips, Andrew; Vock, David M.; Eriobu, Nnakelu; Kwaghe, Vivian; Paredes, Roger; Mateu, Lourdes; Ramachandruni, Srikanth; Narang, Rajeev; Jain, Mamta K.; Lazarte, Susana M.; Baker, Jason V.; Frosch, Anne E.P.; Poulakou, Garyfallia; S... Journal: Lancet Issue: Volume 399:Issue 10324(2022) Page Start: 530 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗